Form 4: Nuvation Bio Inc. Director Anthony Vernon Acquires Stock Options
SEC Form 4
Director Anthony Vernon acquired 200,801 stock options in Nuvation Bio Inc. on September 3, 2024.
Summary
- On September 3, 2024, Anthony Vernon, a director of Nuvation Bio Inc., acquired 200,801 stock options.
- The options have an exercise price of $2.98.
- The options vest on the earlier of the one-year anniversary of the grant date (September 3, 2024) or the next shareholder annual meeting, contingent upon continuous service.
- The expiration date for the options is September 2, 2034.
- Following the transaction, Vernon directly owns 200,801 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to increase company value.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of earliest transaction: Anthony Vernon acquired stock options. |
| 09/03/2024 | Grant date of the stock options. |
| 09/03/2025 | First possible vesting date of the stock options (one-year anniversary). |
| 09/02/2034 | Expiration date of the stock options. |
| 09/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.